The GoodRx Prescription Savings Blog

The latest updates on prescription drugs and ways to save from the GoodRx medical team

What Do Drug Pricing Transparency Laws Mean for You?

by The GoodRx Pharmacist on October 12, 2017 at 5:22 pm

Drugs are expensive, and prices seem to only be increasing. You’ve probably heard of the conflict surrounding popular drugs like Epipen and Daraprim, who each saw large price hikes overnight.

These price increases, among others, have shed necessary light on price hiking and transparency, and have caused many states to take this matter into their own hands. At the moment, 23 states are stepping up their efforts on drug pricing by proposing bills that take on the rising cost of drug pricing.

What is drug pricing transparency?

First off, it’s great for your pocketbook. Drug pricing transparency would require pharmaceutical companies and middlemen (like pharmacy benefit managers) to be less secretive about the actual costs of their medications.

Who would benefit?

Essentially everyone, minus those with a hidden agenda. Providing drug pricing will ensure affordable and accessible prescription drugs for consumers.

What’s going on in California?

Exciting things! Governor Jerry Brown just signed the SB-17 drug transparency bill. This bill requires that pharmaceutical companies give the state of California 60 days notice anytime they plan to raise the price of a drug by 16% or more over 2 years. The companies would also have to explain why the increases are necessary. In addition, health insurers would have to report what percentage of premium increases are caused by drug spending.

California also has another bill, AB-265, which would prohibit drug companies from offering coupons and other discounts to brand-name drugs that have an alternative cheaper generic available. This bill has yet to get to the governor but has passed in the Senate.

And Vermont?

Vermont passed a bill in 2016 that requires pharmaceutical companies to provide justification for drug price hikes.

Each year the Green Mountain Care Board in collaboration with the Department of Vermont Health Access identifies drugs that have experienced price hikes by 50% or more over the past five years, or by 15% more over the past 12 months. For drugs that have experienced increases, the state can fine the pharmaceutical companies.

What about Nevada?

In June, Nevada passed a bill that focuses solely on the cost of diabetes medications. However, it is currently facing lawsuits from pharmaceutical lobbying groups, as they claim that it is unconstitutional and possibly violates patient rights. More to come on this!

What’s going on with the bill in Ohio?

The Ohio Drug Price Act is an initiative that aims to cut pricing. Or does it?

This act would mandate that the state agencies pay no more for prescription drugs than the U.S Department of Veterans Affairs, which typically gets a 24% discount on the price of drugs from pharmaceutical companies.

However, this bill does not apply to those with private health insurance; therefore, if passed Ohioans insured through their employers could actually see drug prices go up in order for the drug companies to regain the money lost from selling to certain buyers at a lower rate.  A similar bill in California flopped just last year!

It seems like more bills are being proposed every day. Stay tuned, we will keep you in the loop.

2016 Year in Review: Good News, Bad News, and Looking Ahead to 2017

by Elizabeth Davis on December 28, 2016 at 6:00 am

As we exit 2016, we can only be certain about one fact regarding the future of health care coverage in America: big changes are ahead. Our healthcare was one of the biggest issues in a bitter Presidential campaign, and President-elect Trump has repeatedly said that he plans to replace Obamacare with something else. We’ll see what that something else is soon.

As politicians fought about the best ways to solve America’s health care challenges, we all suffered. Insurance premiums went up and also provided less coverage. Prices for many brand drugs continued their steady march upwards. There was some good news—exciting new treatments, and a bunch of expensive drugs became available as generics—but in general, 2016 was a painful year, and the prognosis for 2017 isn’t much better.

Here’s a recap.

1. More drugs lost insurance coverage.

The two largest prescription insurance companies, Express Scripts and Caremark, dropped coverage for 40 popular drugs in 2016. Most notably, medications like the popular insulin Lantus, and venlafaxine ER (Effexor XR) for depression have been dropped by Caremark. Express Scripts dropped Taltz for psoriasis, and Orencia for rheumatoid arthritis, among others, and Viekira Pak now has only limited coverage. Insurers are also restricting coverage for many of the expensive (but effective) hepatitis C drugs like Zepatier and Olysio, leaving only Sovaldi and Harvoni as options.

Overall, Caremark will be far more restrictive this year, with a total of 130 drugs excluded from coverage. In contrast, Express Scripts will only have 85 drugs excluded in 2017.

New for 2017—Caremark is dropping coverage based on excluding what they call “hyperinflationary drugs” or drugs that have seen a massive increase in cost. Think EpiPen, Alcortin A, and others you may have seen in the news this year.

Want more information? You can find details and the full list of dropped drugs here. You can also find the Express Scripts formulary here, and Caremark’s formulary here.

2. Even more drugs went generic in 2016. Yay!

There is good news! A number of drugs went generic this year, meaning that more expensive brand name medications now have cheaper alternatives. In some instances, filling a generic instead of a brand can mean a difference of hundreds of dollars, whether you’re insured or paying cash. So this is good news for your healthcare wallet!

Here some of the major drugs that got generic alternatives in 2016:

  • Gleevec (imatinib), an expensive specialty medication used to treat multiple types of cancer, went generic in February. Although the generic, imatinib, is still expensive, it does offer savings over the brand. This is a big deal—Gleevec has been very effective, and a lower cost generic will make it more accessible.
  • Glumetza (metformin ER) is a popular drug used to treat type II diabetes that went generic in February. Glumetza is similar to the other type II diabetes drug Fortamet (also metformin ER), but they differ slightly in how they deliver the drug. You can read more about their similarities and differences here. Also—keep in mind that Glucophage XR has had a less-expensive generic for a few years now, and is still significantly cheaper than Glumetza or Fortamet.
  • Enablex (darifenacin ER), for overactive bladder, went generic in March 2016. Although the generic, darifenacin ER, is on the pricey side, it will save consumers hundreds over the brand name.
  • Nasonex (mometasone) is a popular corticosteroid used to decrease inflammation in the nose and treat the symptoms of allergies. Nasonex’s generic, mometasone, was approved in March.
  • Crestor (rosuvastatin) is a major brand that got a generic alternative in April 2016. Crestor had been dropped by many insurance plans, but with the introduction of a generic alternative, consumers have been able to save big at the pharmacies for this popular statin.
  • Epzicom (abacavir/lamivudine) is an antiretroviral used to treat HIV. Its generic, abacavir/lamivudine became available in October, offering huge savings.
  • Benicar (olmesartan) is another major brand that became available as a generic drug this year. Benicar is a popular medication used to treat high blood pressure, and its generic, olmesartan (available only in tablet form) offers consumers a pretty substantial discount.

3. Insurance costs are going up.

You may have heard that Obamacare (Affordable Care Act or ACA) plan premiums are expected to climb by about 25% in 2017. Because so many insurance companies dropped out of the exchange markets this year, you can expect to pay an average monthly premium of $302, up from $242. Some companies are also raising rates because the premiums they charged initially were too low to cover the costs they faced. Many of these plans also offer limited coverage, especially for prescription drugs.

You can find more information on changes to ACA plans in 2017 here.

You can also expect to see some price increases and changes in coverage if you have a Medicare plan. More plans that ever (up to 85% in 2017) will have a preferred pharmacy network, meaning they will offer the maximum savings only at certain pharmacies. There is some good news here though—the donut hole is shrinking. You’ll owe a smaller percentage of both brand and generic drug costs while in the donut hole.

You can find more specifics on 2017 Medicare plan changes here, and on GoodRx! In May, Goodrx completed a multi-year effort to analyze Medicare drug pricing and help seniors take control of their prescriptions. Read more about it here, or compare Medicare, cash, and coupon prices on GoodRx here.

Of course, many elements the ACA will likely change in 2017 when President-elect Trump takes office . . .

4. 2016 was the year of outrageous drug prices.

The EpiPen drama exploded in the fall of 2016 as outraged parents encountered insane prices for a life-saving prescription. As you may have heard, Mylan, the makers of EpiPen, have raised prices for the lifesaving drug from about $150 to $600 since 2011. There is good news on the horizon though: Mylan has discussed creating a generic alternative to Epipen, and a less expensive epinephrine auto-injector, Auvi-Q, which should return to the market soon.

Insulin prices also continue to increase, with popular options like Lantus, Humalog, and Novolog increasing by around $150 per carton since 2013. This may hit some of you especially hard with Caremark’s decision not to cover Lantus next year.

Some other sky high drug prices continue to include Daraprim, Sovaldi and other hepatitis C drugs, and treatments for very rare conditions like hereditary angioedema (HAE).

What’s in store for 2017?

As you know, Donald Trump is our new president-elect. There are almost definitely changes in prescription and health care costs, and the future of ACA plans is in question. Stay tuned!

There will be more generics released- especially near the end of the 2017. Though none of these are guaranteed, popular drugs like Viagra (sildenafil) for erectile dysfunction, Truvada (emtricitaboine/tenofovir) for HIV treatment, and the expensive epinephrine auto-injector EpiPen (epinephrine) may see more generic alternatives in 2017.

One thing we can all be sure of—it’ll be more important than ever for Americans to be smart healthcare consumers, and GoodRx will be there to help!

Happy holidays and have a happy, healthy new year!

Obamacare Prices Rising in 2017: What You Need to Know

by Elizabeth Davis on November 3, 2016 at 3:02 pm

Open enrollment for 2017 started on Tuesday, November 1 for the Affordable Care Act (ACA or Obamacare) Marketplace. If you’re one of the nearly 14 million Americans expected to sign up for a marketplace plan in 2017, it’s time to make a decision.

You may have heard that Obamacare plan premiums are expected to increase by an average of 25%, which sounds scary—but it isn’t all bad news. Below, we break down what you can expect for 2017, and what you need to know to keep your costs down.

How much will my monthly cost actually go up?

There’s no question that you could see a big increase in your plan costs for 2017. Half of you who buy plans through the exchange will see your monthly payment go up by 16% or more, with an average increase of 25%. It could be much higher depending on where you live though—Phoenix, AZ is expected to see the biggest monthly increase at 145%.

To compare: monthly premiums increased by an estimated 2% in 2015, and 7% in 2016. Not good news for 2017.

Overall, the average monthly premium for adults is estimated to be $302 next year, up from $242 this year, according to a report from the Department of Health and Human Services (DHHS).

Why are prices increasing so much?

According to the Kaiser Family Foundation, premiums are going up in some areas because insurance companies are dropping out of the market, meaning you will have fewer options this year. Some companies are also raising rates because the premiums they charged initially were too low to cover the costs they faced.

Insurers are reporting that more people are buying exchange plans than expected—and they’re using more services than predicted.

There is also speculation that the low number of young, healthy people enrolled is contributing to rising costs. In 2016, only 28% of Americans enrolled in exchange plans were in the 18 – 34 age group—and that number hasn’t really increased since 2014.

Can I choose a different plan to lower my costs?

Maybe. Around 21% of consumers shopping in the federal exchange will find plans from only one insurance company, compared with 2% in 2016.

The DHHS also reports that on average, consumers can choose from 30 total plans in their county—down from 47 plans in 2016.

Yes, less choice is a bad thing. But keep things in perspective—you would likely have fewer choices with an employer-sponsored plan. According a 2015 survey, 30% of Americans with insurance through their employer were only offered a single plan from a single provider.

However—even with fewer options, you can still try to change your plan to lower your monthly costs. The DHHS report estimates that if all consumers switched from their current plan to the lowest premium plan in the same “metal” level (Silver, Gold, Bronze, or Platinum), the average 2017 monthly premium after tax credits would be $28 less than 2016.

Obviously, this could mean a decrease in your coverage as well, but if your goal is to lower your monthly premium, it’s worth considering.

What about subsidies?

Subsidies are discounts on your monthly payment meant to reduce your out-of-pocket cost if your income is under a certain amount. You qualify for these discounts if you are under 65 and making between 100% and 400% of the federal poverty level (FPL).

If you make under 250% of the FPL, you’re also eligible for reductions on silver plans—and if you make under 138%, you’re eligible for Medicaid.

84% of people buying a plan on the exchange qualified for at least some subsidy in 2016, and it should stay about the same in 2017.

What if I would rather pay the penalty?

As you probably know, there is now a penalty fee for being uninsured. Be aware that the penalty could top $700 per person or $2100 per household in 2017. In 2016, your penalty for being uninsured was 2.5% of the total household adjusted gross income, or $695 per adult and $347.50 per child. The maximum penalty in 2016 was $2085.

In 2017, the 2.5% percentage will stay the same, but the flat fees will be adjusted for inflation.

Are there ways to avoid the penalty and still not pay for insurance?

There are a few ways to claim an exemption from the penalty, including:

  • The most affordable coverage available to you costs more than 8% of your household income.
  • You are exempt from filing a tax return because your income is too low.
  • You were uninsured for fewer than three months of the year.
  • You qualify for a hardship exemption (due to issues like homelessness, bankruptcy, or eviction).

You can check for more ways to qualify and apply for an exemption on

I want to get a plan through the exchange—what else can I do to save?

  • Shop around on the exchange. More than 70% of current marketplace enrollees should be able to find a plan for $75 or less in premiums per month, after applicable tax credits in 2017. 77% will be able to find a plan for less than $100 per month (including rebates).
  • Need a particular prescription, procedure, or type of care covered? Do your research—go online or call the plan provider to find out if the plan you’re considering offers coverage that will work for you.
  • Find other ways to save. If you’re paying out of pocket until you hit a high deductible, GoodRx can help you compare prices, and potentially help with your prescription costs. Also consider pharmacy membership programs—many pharmacies offer free or discounted generic prescriptions (like atorvastatin, lisinopril, metformin, and some antibiotics)—and manufacturer discounts.
  • Free preventive care. Vaccinations and screening for many common conditions are free for all adults, and contraceptives are free for women. Some plans will even provide breastfeeding equipment and counseling for pregnant and nursing women.

What Is Proposition 61?

by The GoodRx Pharmacist on October 25, 2016 at 1:28 pm

The increased cost of prescription drugs has been all over the news—and a topic for debate in the 2016 elections.

Huge price hikes for medications like EpiPen, Thiola, and Daraprim, just to name a few, have left Americans frustrated and angry. Amid the controversy, some states (including California and Ohio) are trying to address drug pricing on the ballot this fall—a bold move that other states will likely follow.

What would the Drug Price Relief Act do?

The Drug Price Relief Act (Proposition 61 in California) would cap the price any state agency or health care program could spend on prescription drugs. The cap would be set at the price paid by the US Department of Veteran Affairs—which usually receives the biggest discount.

That would mean that the cost of medications would mimic the low prices of the VA system, pricing drugs 20-24% lower than any other current government program.

What drugs are covered in the VA system?

The VA drug formulary (the drugs covered by the program) is extremely limited, which helps to reduce costs. Fewer drugs are covered, but prices are significantly better for those drugs.

What is the opposition saying?

Those who oppose the drug relief act think that this proposition could drive drug prices even higher. The fear is that drug companies will raise prices overall in order to continue profiting (or simply not sell their drugs to the VA), which could have a wider negative impact.

What are supporters saying?

Those in favor of the drug relief act believe that California’s proposition will fight the price-gouging we are seeing from pharmaceutical companies and provide better access to life-saving medications.

Who is in support of the drug price relief act?

Some of the biggest supporters of the drug price relief act include Bernie Sanders and the AIDS Healthcare Foundation but there are many others.

Will Ohio have it on the ballot this November?

No. Ohio will not be voting on a drug relief act this year. If all goes well, it might appear on next year’s ballot.

Will California have it on the ballot this November?

Yes. California will be voting on Proposition 61, the Drug Price Standards Initiative, as an initiated state statute. This means that if Proposition 61 passes it will become a new law.

Higher 2017 Premiums Could Mean Trouble for Obamacare

by Doug Hirsch on October 6, 2016 at 12:18 pm

More than six years after its passing, Obamacare remains controversial.

In the past few weeks, states have begun to approve premium rate increases for 2017 ACA (Affordable Care Act) health plans. (Insurance carriers need to submit their rate changes to a state commission, which can then approve or deny their request.)

So far, it’s not pretty. Average 2017 monthly premium rates for individuals will likely increase by about 25%. In some states, increases are projected to be 50% or higher. While some increases might naturally be expected, these are surprisingly high and a troubling sign for the future of Obamacare. It’s also worth noting that coverage under these plans, especially for prescription drugs, can be very limited.

In addition, a number of carriers have dropped out of the markets, decreasing competition.

There are a number of reasons for the price hikes—many reports mention that fewer young, healthy people are signing up than expected.

Many people have called for Obamacare to simply be terminated. However, it’s not that simple. There are many aspects of the program that most Americans support, such as eliminating pre-existing condition limitations and providing lifetime caps on patient out-of-pocket spending.

Also, if you ended Obamacare, what would you replace it with?

This week, Megan McArdle at Bloomberg wrote an insightful article about the challenges facing the program and potential fixes. She pointed out that any potential fixes are fraught with challenges. Some possibilities include:

  • Increase subsidies. Have the government offset the rising premiums with greater subsidies. This seems unlikely to pass in our current political climate.
  • Increase penalties. Some argue that Obamacare only works when everyone is signed up—both sick and healthy individuals. Current penalties for folks who don’t sign up aren’t severe, so many people just don’t bother. In theory, if more healthy people are paying premiums, it would bring down the average cost for everyone.
  • Provide a public option. Create a government-run health plan to compete with the carriers and offer coverage when the private sector won’t.
  • Scrap the whole thing. Republicans have talked of replacing Obamacare with a private option, with less government involvement, less regulation, and greater use of consumer-directed health savings accounts.

At GoodRx, we don’t have the answer. We do know (because you tell us) that insurance providers—both Obamacare and private plans—continue to shrink their prescription drug benefits and you’re left paying a bigger bill. While GoodRx can’t control insurance premiums, we will continue to find new ways to help consumers get the medications they need at a price they can afford.

Copyright ©2015 GoodRx, Inc.

This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment. Third party logos, trademarks, brand names and images contained on are for demonstration purposes only and are owned by their respective rights holders, who are not affiliated with this Site.